Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema

Roc&iacute;o Herrero-Vanrell1, Jose Augusto Cardillo2, Baruch D Kuppermann31Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Complutense University, Madrid, Spain; 2Hospital de Olhos de Araraquara, Araraquara, S&atilde;o Paulo, Brazil; 3Gavin Herbert Eye Inst...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roc&iacute;o Herrero-Vanrell,&nbsp;Jose Augusto Cardillo, Baruch D Kuppermann
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6b0e530549074eb882b617601866241c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6b0e530549074eb882b617601866241c
record_format	dspace
spelling	oai:doaj.org-article:6b0e530549074eb882b617601866241c2021-12-02T09:19:01ZClinical applications of the sustained-release dexamethasone implant for treatment of macular edema1177-54671177-5483https://doaj.org/article/6b0e530549074eb882b617601866241c2011-02-01T00:00:00Zhttp://www.dovepress.com/clinical-applications-of-the-sustained-release-dexamethasone-implant-f-a6175https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Roc&iacute;o Herrero-Vanrell1, Jose Augusto Cardillo2, Baruch D Kuppermann31Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Complutense University, Madrid, Spain; 2Hospital de Olhos de Araraquara, Araraquara, S&atilde;o Paulo, Brazil; 3Gavin Herbert Eye Institute, University of California, Irvine, CA, USAAbstract: Macular edema is one of the leading causes of vision loss among patients with retinal vein occlusion, diabetic retinopathy, and posterior chamber inflammatory disease. However, the treatment of macular edema is considerably limited by the difficulty in delivering effective doses of therapeutic agents into the vitreous cavity. In recent years, the development of a sustained-release dexamethasone intravitreal implant (Ozurdex&reg;) has enabled more controlled drug release at a stable rate over a long period of time, with a potentially lower rate of adverse events. Clinical studies indicate that this dexamethasone implant is a promising new treatment option for patients with persistent macular edema resulting from retinal vein occlusion, diabetic retinopathy, and uveitis or Irvine-Gass syndrome.Keywords: diabetic retinopathy, macular edema, Ozurdex&reg;, posterior-segment inflammatory disease, retinal vein occlusion, sustained-release dexamethasone implant Roc&iacute;o Herrero-Vanrell,&nbsp;Jose Augusto CardilloBaruch D KuppermannDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 139-146 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Roc&iacute;o Herrero-Vanrell,&nbsp;Jose Augusto Cardillo Baruch D Kuppermann Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
description	Roc&iacute;o Herrero-Vanrell1, Jose Augusto Cardillo2, Baruch D Kuppermann31Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Complutense University, Madrid, Spain; 2Hospital de Olhos de Araraquara, Araraquara, S&atilde;o Paulo, Brazil; 3Gavin Herbert Eye Institute, University of California, Irvine, CA, USAAbstract: Macular edema is one of the leading causes of vision loss among patients with retinal vein occlusion, diabetic retinopathy, and posterior chamber inflammatory disease. However, the treatment of macular edema is considerably limited by the difficulty in delivering effective doses of therapeutic agents into the vitreous cavity. In recent years, the development of a sustained-release dexamethasone intravitreal implant (Ozurdex&reg;) has enabled more controlled drug release at a stable rate over a long period of time, with a potentially lower rate of adverse events. Clinical studies indicate that this dexamethasone implant is a promising new treatment option for patients with persistent macular edema resulting from retinal vein occlusion, diabetic retinopathy, and uveitis or Irvine-Gass syndrome.Keywords: diabetic retinopathy, macular edema, Ozurdex&reg;, posterior-segment inflammatory disease, retinal vein occlusion, sustained-release dexamethasone implant
format	article
author	Roc&iacute;o Herrero-Vanrell,&nbsp;Jose Augusto Cardillo Baruch D Kuppermann
author_facet	Roc&iacute;o Herrero-Vanrell,&nbsp;Jose Augusto Cardillo Baruch D Kuppermann
author_sort	Roc&iacute;o Herrero-Vanrell,&nbsp;Jose Augusto Cardillo
title	Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
title_short	Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
title_full	Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
title_fullStr	Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
title_full_unstemmed	Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
title_sort	clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/6b0e530549074eb882b617601866241c
work_keys_str_mv	AT rocampiacuteoherrerovanrellampnbspjoseaugustocardillo clinicalapplicationsofthesustainedreleasedexamethasoneimplantfortreatmentofmacularedema AT baruchdkuppermann clinicalapplicationsofthesustainedreleasedexamethasoneimplantfortreatmentofmacularedema
_version_	1718398188876988416

Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema

Ejemplares similares